Under the terms of the collaboration, AvantGen is responsible for generating novel antibodies to specified cancer targets using its proprietary human antibody yeast display technology platform.
AvantGen to use its proprietary human antibody yeast display platform to generate additional novel cancer therapeutic antibody drug candidates for Tanabe Research Laboratories USA
SAN DIEGO--(BUSINESS WIRE)-- AvantGen, a privately-held antibody discovery and optimization service provider, today announced the successful completion of a first cancer therapeutic antibody discovery program and initiation of a second program for Tanabe Research Laboratories USA, Inc. (TRL).
Under the terms of the collaboration, AvantGen is responsible for generating novel antibodies to specified cancer targets using its proprietary human antibody yeast display technology platform. TRL has worldwide rights to develop and commercialize antibodies discovered by AvantGen. AvantGen receives upfront payments and is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the collaboration.
“AvantGen’s antibody discovery and optimization services have been extensively validated against hundreds of targets primarily through numerous NIH SBIR I and II funded projects. Since the recent introduction of our new, state-of-the-art human antibody discovery and optimization platform, this second project with TRL represents the 15th de novo antibody discovery project we have initiated specifically for corporate partners,” said Xiaomin Fan, Ph.D., founder and president of AvantGen. “The platform utilizes advantageous technologies, including a robust yeast display system, large natural human antibody database and fully human antibody libraries, for the generation of antibodies to meet challenging design goals for therapeutic, diagnostic and research tool purposes.”
“The therapeutic antibody discovery program conducted by AvantGen was highly collaborative and was accomplished faster than expected, without the need to further optimize the antibodies in order to meet TRL’s design goals,” said Roland Newman, Ph.D., chief scientific officer for TRL. “We look forward to working together on the second program and others in the future.”
About AvantGen
AvantGen, Inc is a privately-held antibody discovery and optimization service provider and a leader in the use of yeast display technology for antibody discovery and optimization. Founded by experts in the creation of antibody discovery and optimization platforms, AvantGen excels in the rapid, cost-effective generation of antibodies for therapeutic, diagnostic and research tool applications. The Company’s platform includes a robust yeast display system, large natural human antibody database, fully human antibody libraries comprised of over 100 billion antibody clones, flow cytometry-based and other screening technologies, as well as novel methodologies for rabbit monoclonal antibody generation. This versatile platform can be used to discover and optimize antibodies directed at specific disease targets, affinity mature existing antibodies to improve their binding properties and humanize antibodies to render non-human antibodies suitable for human therapeutic applications, as well as generate rabbit monoclonal antibodies for applications that need extremely high specificity, such as antibodies capable of distinguishing point mutations and post-translational modifications for IHC, and anti-idiotype antibodies for PK studies. AvantGen’s partners include pharmaceutical, biotech, diagnostic and government entities, many of which are repeat customers. For more information, visit www.avantgen.com.
About Tanabe Research Laboratories U.S.A., Inc. (TRL)
TRL is an independent subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) located in San Diego California, whose role is to discover and develop biological drug candidates for therapy. Currently, TRL’s efforts are directed towards antibody and antibody-related research to target tumors and other diseases with high unmet needs. TRL is establishing collaborative relationships with other companies and academic research organizations to further its goals of identifying preclinical therapeutic lead compounds for development. http://www.trlusa.com/
View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005323/en/
Source: AvantGen, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180104005323/en
